Share on StockTwits
 

Alexion Pharmaceuticals (NASDAQ:ALXN) EVP Stephen P. Squinto sold 36,989 shares of the stock on the open market in a transaction dated Tuesday, February 4th. The shares were sold at an average price of $155.12, for a total transaction of $5,737,733.68. Following the completion of the transaction, the executive vice president now directly owns 94,818 shares in the company, valued at approximately $14,708,168. The sale was disclosed in a legal filing with the SEC, which is available at this link.

Several analysts have recently commented on the stock. Analysts at Zacks reiterated a “neutral” rating on shares of Alexion Pharmaceuticals in a research note to investors on Tuesday. They now have a $170.00 price target on the stock. Separately, analysts at UBS AG raised their price target on shares of Alexion Pharmaceuticals from $150.00 to $185.00 in a research note to investors on Friday, January 31st. Finally, analysts at Jefferies Group raised their price target on shares of Alexion Pharmaceuticals from $106.00 to $145.00 in a research note to investors on Friday, January 31st. They now have a “hold” rating on the stock. One investment analyst has rated the stock with a sell rating, five have given a hold rating and thirteen have assigned a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average price target of $153.67.

Alexion Pharmaceuticals (NASDAQ:ALXN) traded down 1.10% during mid-day trading on Wednesday, hitting $154.49. The stock had a trading volume of 1,416,879 shares. Alexion Pharmaceuticals has a 1-year low of $81.82 and a 1-year high of $169.98. The stock’s 50-day moving average is $137.4 and its 200-day moving average is $120.4. The company has a market cap of $30.346 billion and a price-to-earnings ratio of 123.00.

Alexion Pharmaceuticals (NASDAQ:ALXN) last posted its quarterly earnings results on Thursday, January 30th. The company reported $0.87 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.83 by $0.04. The company had revenue of $441.90 million for the quarter, compared to the consensus estimate of $430.08 million. Analysts expect that Alexion Pharmaceuticals will post $3.87 EPS for the current fiscal year.

Alexion Pharmaceuticals, Inc (NASDAQ:ALXN) is a biopharmaceutical company focused on serving patients with severe and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.